Franklin Genomic Advancements ETF (HELX)

BATS: HELX · Real-Time Price · USD

38.83

-0.92 (-2.30%)

At close: Jul 31, 2026, 4:00 PM EDT

38.83

0.00 (0.00%)

After-hours: Jul 31, 2026, 8:00 PM EDT

-2.30% (1D)

Assets	$29.13M
Expense Ratio	0.50%
PE Ratio	33.05
Shares Out	750,000
Dividend (ttm)	$0.14
Dividend Yield	0.37%
Ex-Dividend Date	Dec 30, 2025
Payout Frequency	n/a
Payout Ratio	12.18%

Volume	4,274
Open	39.15
Previous Close	39.75
Day's Range	38.72 - 39.15
52-Week Low	27.54
52-Week High	41.30
Beta	0.97
Holdings	65
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

Asset Class Equity

Category Health

Region Global

Stock Exchange BATS

Ticker Symbol HELX

ETF Provider Franklin Templeton

Top 10 Holdings

47.03% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	9.31%
Natera, Inc.	NTRA	7.44%
Krystal Biotech, Inc.	KRYS	5.70%
Ligand Pharmaceuticals Incorporated	LGND	4.52%
Adaptive Biotechnologies Corporation	ADPT	4.25%
BridgeBio Pharma, Inc.	BBIO	3.99%
United Therapeutics Corporation	UTHR	3.51%
Eli Lilly and Company	LLY	2.99%
Vertex Pharmaceuticals Incorporated	VRTX	2.68%
Travere Therapeutics, Inc.	TVTX	2.65%

View More Holdings

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 30, 2025	$0.14334	Jan 8, 2026
Dec 30, 2021	$0.00394	Jan 7, 2022
Dec 13, 2021	$0.11415	Dec 21, 2021
Dec 14, 2020	$0.05178	Dec 23, 2020

Full Dividend History

Performance

HELX had a total return of 38.74% in the past year, including dividends. Since the fund's inception, the average annual return has been 7.84%.